New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload ...
New Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy Plinabulin’s GEF-H1 ...
SEATTLE--(BUSINESS WIRE)--ProfoundBio, a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the ...
This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...
The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects. There is still more work to be done to refine ...
Antibody-Drug Conjugates (ADCs) are an exciting new class of drugs that offers clinical benefits to a wide range of cancers. Unlike immune modulating monoclonal antibodies (mAbs) such as checkpoint ...
Merck MRK announced that a phase II/III study has been initiated on its CDH6-directed DXd antibody-drug conjugate, raludotatug deruxtecan (R-DXd), in patients with platinum-resistant ovarian cancer.
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results